STIFEL 2026 HEALTHCARE CONFERENCE - OUTSET MEDICAL INC

Explicit Guidance:

• Revenue: Maintained FY2026 guidance range of $125 million–$130 million; expects back-half 2026 growth rate of ~17% off the first half.
• Future Growth Ambition: Targets double-digit revenue growth for FY2027 and future years.
• Margins: Long-term gross margin target of 50% remains valid, with a planning horizon of 3–5 years; expects near-term margin compression from higher console mix, but future growth driven by high-margin software/data services to accelerate toward this goal.
• Refresh Opportunity: Cites a $150 million revenue opportunity over the "next couple of years" specifically from console refreshes.

Business-Segment Outlook:

• Acute Care (Core): Currently 85% of revenue; expected to remain the primary focus for top-line growth and margin expansion in the near term to drive profitability.
• Home Dialysis: Positioned as a long-term growth engine; driver for home acceleration is high patient retention rates (>90%) and expansion of provider networks, rather than immediate technology shifts.
• Revenue Mix Drivers:
  • Refresh Sales: Targeting ~3,000 consoles reaching end-of-life (7-year useful life) in 2027–2028, creating a recurring "wave" of replacement revenue.
  • Expansion: Significant pipeline in "same-store" expansion (ICU to non-ICU and vice versa) and health-system-wide rollout across existing customer facilities.
  • New Customer Acquisition: Continued focus on "white space" hospitals currently outsourced to third-party dialysis providers.
• EMR & Data Services: EMR integration (Epic/Cerner) revenue grew >20%; strategy involves upfront implementation fees plus annual maintenance/subscription fees. Future growth anticipated via AI-driven analytics and connectivity to customer BI tools (Tableau, Power BI, QuickSight).

Market and Competitive Outlook:

• Product Launch: Next-gen Tableau system development underway; full release targeted for late Q4 2026 or early 2027.
  • Differentiation: Emphasis on cybersecurity (meeting 2025 FDA requirements), reliability, and operational readiness over speed of rollout.
  • Pricing & Margins: Anticipates ability to price the next-gen system at a higher point due to added value (cybersecurity, software features), with net accretive impact on gross margins despite higher hardware costs.
• Competitive Positioning: Uniquely positioned with direct EMR integration and proprietary data streaming (1M+ treatments/year, 3.5M data points/treatment) to enable AI use cases and stickiness.
• Sales Force Strategy: Refinements to territory sizing and compensation to focus on total revenue stack (recurring + capital) and deeper penetration of existing large accounts rather than chasing only new logos.

Macro / Industry Outlook:

• Regulatory/Policy: HHS "landmark national plan" to transform kidney care is viewed as a tailwind; management sees bipartisan consensus on home dialysis and new tech adoption, mitigating political risk regarding policy delays.
• Hospital Economics: Hospital budget tightening is viewed as a benefit for Outset; customers are prioritizing "bottom-line" cost reduction (projected 50%+ savings via insourcing with Tableau) over top-line revenue generation.
• Market Dynamics: Expectation of structural shifts in care delivery to increase patient choice and access to new technologies.

Strategic Initiatives:

• Product Innovation: Next-gen Tableau release focused on software, data, and cybersecurity enhancements; roadmap includes AI-centric programs to improve service efficiency and gross margins.
• Clinical Support: Established a Clinical Excellence Team to drive internal facility expansion by demonstrating clinical and financial results to existing customers.
• Home Ecosystem: Partner expansion (horizontal and vertical); average patient training time reduced to 10–14 days (matching PD gold standard) to facilitate home adoption.
• M&A/Partnerships: No specific M&A mentioned; focus is on organic growth and deepening relationships with current large health systems (e.g., HCA validation).

Risks and Headwinds to Outlook:

• Regulatory Timeline: Uncertainty regarding the speed and specifics of HHS policy implementation following the recent national plan.
• Product Rollout Execution: Commitment to a "slow, methodical, deliberate" next-gen release to avoid "doing harm" to the 1,000+ site install base; speed is sacrificed for quality, potentially delaying near-term ramp.
• Economic Sensitivity: While cost-cutting is a driver, potential tightening of capital spending or changes in Medicare/Medicaid/NIH funding could impact top-line revenue generation.
• Sales Cycle Length: Capital equipment cycle remains 9–12 months, though post-sale utilization is highly durable.
• Refresh Timing: Patient census fluctuations may cause some customers to delay refreshes beyond the 7-year life, shifting revenue to future periods.

Management Tone on the Future:

• Confidence: High confidence in the "sediment layers" of growth (refresh, expansion, new acquisition) and the structural tailwinds from cost-conscious hospital environments.
• Prudence: Maintains "thoughtful, prudent conservatism" by holding 2026 guidance flat despite Q3 beat to ensure strong foundation for 2027; prioritizes long-term recurring revenue stability over short-term acceleration.
• Strategic Patience: Explicitly choosing a slower rollout for the next-gen system to ensure "customer experience" precedes "speed."

Miscellaneous:

• Revenue Quality: >70% of total revenue is recurring; ~50% is from consumables (treatments).
• Customer Validation: Secured first refresh agreement with HCA (largest US health system), serving as a key validation for future refresh cycles.
• AI Strategy: Active ideation on using 10 trillion data points in the cloud to drive clinical value and service efficiency via AI.